Psilopatis Iason, Garmpis Nikolaos, Garmpi Anna, Vrettou Kleio, Sarantis Panagiotis, Koustas Evangelos, Antoniou Efstathios A, Dimitroulis Dimitrios, Kouraklis Gregory, Karamouzis Michail V, Marinos Georgios, Kontzoglou Konstantinos, Nonni Afroditi, Nikolettos Konstantinos, Fleckenstein Florian N, Zoumpouli Christina, Damaskos Christos
Department of Gynecology, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
Second Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Cancers (Basel). 2023 Apr 10;15(8):2222. doi: 10.3390/cancers15082222.
Cervical carcinoma is one of the most common cancers among women globally. Histone deacetylase inhibitors (HDACIs) constitute anticancer drugs that, by increasing the histone acetylation level in various cell types, induce differentiation, cell cycle arrest, and apoptosis. The aim of the current review is to study the role of HDACIs in the treatment of cervical cancer. A literature review was conducted using the MEDLINE and LIVIVO databases with a view to identifying relevant studies. By employing the search terms "histone deacetylase" and "cervical cancer", we managed to identify 95 studies published between 2001 and 2023. The present work embodies the most up-to-date, comprehensive review of the literature centering on the particular role of HDACIs as treatment agents for cervical cancer. Both well-established and novel HDACIs seem to represent modern, efficacious anticancer drugs, which, alone or in combination with other treatments, may successfully inhibit cervical cancer cell growth, induce cell cycle arrest, and provoke apoptosis. In summary, histone deacetylases seem to represent promising future treatment targets in cervical cancer.
宫颈癌是全球女性中最常见的癌症之一。组蛋白去乙酰化酶抑制剂（HDACIs）是一类抗癌药物，通过提高各种细胞类型中的组蛋白乙酰化水平，诱导分化、细胞周期停滞和凋亡。本综述的目的是研究HDACIs在宫颈癌治疗中的作用。使用MEDLINE和LIVIVO数据库进行文献综述，以识别相关研究。通过使用搜索词“组蛋白去乙酰化酶”和“宫颈癌”，我们成功识别了2001年至2023年期间发表的95项研究。本研究是对以HDACIs作为宫颈癌治疗药物的特殊作用为中心的文献的最新、最全面的综述。成熟的和新型的HDACIs似乎都是现代有效的抗癌药物，单独或与其他治疗方法联合使用，可能成功抑制宫颈癌细胞生长、诱导细胞周期停滞并引发凋亡。总之，组蛋白去乙酰化酶似乎是宫颈癌未来有前景的治疗靶点。
Zotero 插件
